Loading
Obinutuzumab with chemotherapy and as maintenance kept follicular lymphoma from progressing for longer than rituximab, at the cost of more serious side effects.
Open-label phase 3 trial: 1,202 patients with previously untreated follicular lymphoma were randomised to obinutuzumab or rituximab with bendamustine, CHOP or CVP, followed by antibody maintenance.
At a planned interim analysis after a median follow-up of 34.5 months, estimated three-year progression-free survival was 80.0 percent with obinutuzumab against 73.3 percent with rituximab (hazard ratio 0.66). Response rates were similar (88.5 against 86.9 percent); grade 3 to 5 adverse events (74.6 against 67.8 percent) and serious adverse events (46.1 against 39.9 percent) were more frequent with obinutuzumab, and infusion-related events were the most common adverse event.
Obinutuzumab-based immunochemotherapy is a first-line option for follicular lymphoma; the choice against rituximab weighs longer progression-free survival against toxicity and cost.
Shares Rituximab, Follicular lymphoma, New England Journal of Medicine.
Shares Rituximab, Follicular lymphoma.
Shares Obinutuzumab, Rituximab, Follicular lymphoma.
Shares Rituximab, Follicular lymphoma.
Shares Rituximab, New England Journal of Medicine.
Shares Obinutuzumab, Rituximab.
Shares GALLIUM, Obinutuzumab, Rituximab, Follicular lymphoma.
Shares Rituximab, Follicular lymphoma.